Literature DB >> 27784795

The Potential Roles of Long Noncoding RNAs (lncRNA) in Glioblastoma Development.

Shuang Liu1, Ramkrishna Mitra2,3, Ming-Ming Zhao1, Wenhong Fan4, Christine M Eischen2, Feng Yin1, Zhongming Zhao3,5,6.   

Abstract

Long noncoding RNA (lncRNA) may contribute to the initiation and progression of tumor. In this study, we first systematically compared lncRNA and mRNA expression between glioblastoma and paired normal brain tissues using microarray data. We found 27 lncRNA and 82 mRNA significantly upregulated in glioblastoma, as well as 198 lncRNA and 285 mRNA significantly downregulated in glioblastoma. We identified 138 coexpressed lncRNA-mRNA pairs from these differentially expressed lncRNA and genes. Subsequent pathway analysis of the lncRNA-paired genes indicated that EphrinB-EPHB, p75-mediated signaling, TNFα/NF-κB, and ErbB2/ErbB3 signaling pathways might be altered in glioblastoma. Specifically, lncRNA RAMP2-AS1 had significant decrease of expression in glioblastoma tissues and showed coexpressional relationship with NOTCH3, an important tumor promoter in many neoplastic diseases. Our follow up experiment indicated that (i) an overexpression of RAMP2-AS1 reduced glioblastoma cell proliferation in vitro and also reduced glioblastoma xenograft tumors in vivo; (ii) NOTCH3 and RAMP2-AS1 coexpression rescued the inhibitory action of RAMP2-AS1 in glioblastoma cells; and (iii) RNA pull-down assay revealed a direct interaction of RAMP2-AS1 with DHC10, which may consequently inhibit, as we hypothesize, the expression of NOTCH3 and its downstream signaling molecule HES1 in glioblastoma. Taken together, our data revealed that lncRNA expression profile in glioblastoma tissue was significantly altered; and RAMP2-AS1 might play a tumor suppressive role in glioblastoma through an indirect inhibition of NOTCH3 Our results provided some insights into understanding the key roles of lncRNA-mRNA coregulation in human glioblastoma and the mechanisms responsible for glioblastoma progression and pathogenesis. Mol Cancer Ther; 15(12); 2977-86. ©2016 AACR. ©2016 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27784795      PMCID: PMC5136321          DOI: 10.1158/1535-7163.MCT-16-0320

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  55 in total

Review 1.  Molecular mechanisms of long noncoding RNAs.

Authors:  Kevin C Wang; Howard Y Chang
Journal:  Mol Cell       Date:  2011-09-16       Impact factor: 17.970

2.  RNA splicing control: yet another gene regulatory role for long nuclear noncoding RNAs.

Authors:  Xinying Zong; Vidisha Tripathi; Kannanganattu V Prasanth
Journal:  RNA Biol       Date:  2011-11-01       Impact factor: 4.652

3.  Overexpression of the long non-coding RNA MEG3 impairs in vitro glioma cell proliferation.

Authors:  Pengjun Wang; Zhongqiao Ren; Piyun Sun
Journal:  J Cell Biochem       Date:  2012-06       Impact factor: 4.429

4.  Notch3 activation promotes invasive glioma formation in a tissue site-specific manner.

Authors:  Tarran J Pierfelice; Karisa C Schreck; Louis Dang; Laura Asnaghi; Nicholas Gaiano; Charles G Eberhart
Journal:  Cancer Res       Date:  2011-01-18       Impact factor: 12.701

5.  Long non-coding RNAs as potential biomarkers and therapeutic targets for gliomas.

Authors:  Yuanzhao Sun; Zhong Wang; Dai Zhou
Journal:  Med Hypotheses       Date:  2013-05-18       Impact factor: 1.538

6.  Long non-coding RNA H19 regulates glioma angiogenesis and the biological behavior of glioma-associated endothelial cells by inhibiting microRNA-29a.

Authors:  Peng Jia; Heng Cai; Xiaobai Liu; Jiajia Chen; Jun Ma; Ping Wang; Yunhui Liu; Jian Zheng; Yixue Xue
Journal:  Cancer Lett       Date:  2016-08-16       Impact factor: 8.679

7.  TAN-1, the human homolog of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms.

Authors:  L W Ellisen; J Bird; D C West; A L Soreng; T C Reynolds; S D Smith; J Sklar
Journal:  Cell       Date:  1991-08-23       Impact factor: 41.582

8.  Uncovering MicroRNA and Transcription Factor Mediated Regulatory Networks in Glioblastoma.

Authors:  Jingchun Sun; Xue Gong; Benjamin Purow; Zhongming Zhao
Journal:  PLoS Comput Biol       Date:  2012-07-19       Impact factor: 4.475

9.  Large-scale prediction of long non-coding RNA functions in a coding-non-coding gene co-expression network.

Authors:  Qi Liao; Changning Liu; Xiongying Yuan; Shuli Kang; Ruoyu Miao; Hui Xiao; Guoguang Zhao; Haitao Luo; Dechao Bu; Haitao Zhao; Geir Skogerbø; Zhongdao Wu; Yi Zhao
Journal:  Nucleic Acids Res       Date:  2011-01-18       Impact factor: 16.971

10.  Pint lincRNA connects the p53 pathway with epigenetic silencing by the Polycomb repressive complex 2.

Authors:  Oskar Marín-Béjar; Francesco P Marchese; Alejandro Athie; Yolanda Sánchez; Jovanna González; Victor Segura; Lulu Huang; Isabel Moreno; Alfons Navarro; Mariano Monzó; Jesús García-Foncillas; John L Rinn; Shuling Guo; Maite Huarte
Journal:  Genome Biol       Date:  2013       Impact factor: 13.583

View more
  25 in total

1.  A Balanced Reciprocal Translocation t(2;9)(p25;q13) Disrupting the LINC00299 Gene in a Patient with Intellectual Disability.

Authors:  Halinna Dornelles-Wawruk; Romina Soledad Heredia; Milton R de Paula-Junior; Maria Terezinha O Cardoso; Raphael S Bonadio; Bianca F Dos Reis; Aline Pic-Taylor; Silviene F de Oliveira; Juliana F Mazzeu
Journal:  Mol Syndromol       Date:  2019-06-12

Review 2.  Prognostic and clinicopathological significance of long non-coding RNA in glioma.

Authors:  Junhong Li; Ruofei Liang; Chen Song; Yufan Xiang; Yanhui Liu
Journal:  Neurosurg Rev       Date:  2018-03-21       Impact factor: 3.042

3.  LINC00473 antagonizes the tumour suppressor miR-195 to mediate the pathogenesis of Wilms tumour via IKKα.

Authors:  Shibo Zhu; Wen Fu; Liyu Zhang; Kai Fu; Jinhua Hu; Wei Jia; Guochang Liu
Journal:  Cell Prolif       Date:  2017-11-20       Impact factor: 6.831

4.  Design, Synthesis, and Biological Evaluation of Novel Allosteric Protein Disulfide Isomerase Inhibitors.

Authors:  Suhui Yang; Andrea Shergalis; Dan Lu; Anahita Kyani; Ziwei Liu; Mats Ljungman; Nouri Neamati
Journal:  J Med Chem       Date:  2019-04-02       Impact factor: 7.446

5.  Highly deregulated lncRNA LOC is associated with overall worse prognosis in Hepatocellular Carcinoma patients.

Authors:  Lee Jin Lim; Lay Hiang Ling; Yu Pei Neo; Alexander Y F Chung; Brian K P Goh; Pierce K H Chow; Chung Yip Chan; Peng Chung Cheow; Ser Yee Lee; Tony K H Lim; Samuel S Chong; London L P J Ooi; Caroline G Lee
Journal:  J Cancer       Date:  2021-03-30       Impact factor: 4.207

6.  HAfTs are novel lncRNA transcripts from aflatoxin exposure.

Authors:  B Alex Merrick; Justin S Chang; Dhiral P Phadke; Meredith A Bostrom; Ruchir R Shah; Xinguo Wang; Oksana Gordon; Garron M Wright
Journal:  PLoS One       Date:  2018-01-19       Impact factor: 3.240

7.  Comprehensive Profiling of lincRNAs in Lung Adenocarcinoma of Never Smokers Reveals Their Roles in Cancer Development and Prognosis.

Authors:  Ying Li; Zheng Wang; Asha Nair; Wei Song; Ping Yang; Xiaoju Zhang; Zhifu Sun
Journal:  Genes (Basel)       Date:  2017-11-13       Impact factor: 4.096

8.  H19, a Long Non-coding RNA, Mediates Transcription Factors and Target Genes through Interference of MicroRNAs in Pan-Cancer.

Authors:  Aimin Li; Saurav Mallik; Haidan Luo; Peilin Jia; Dung-Fang Lee; Zhongming Zhao
Journal:  Mol Ther Nucleic Acids       Date:  2020-05-27       Impact factor: 8.886

9.  Expression Analysis of Long Non-Coding RNAs Related With FOXM1, GATA3, FOXA1 and ESR1 in Breast Tissues.

Authors:  Bita Hassani; Mohammad Taheri; Yazdan Asgari; Ali Zekri; Ali Sattari; Soudeh Ghafouri-Fard; Farkhondeh Pouresmaeili
Journal:  Front Oncol       Date:  2021-05-19       Impact factor: 6.244

10.  LncRNA TCONS_00004099-derived microRNA regulates oncogenesis through PTPRF in gliomas.

Authors:  Yuhao Wang; Aijun Shan; Zhiwei Zhou; Wenpeng Li; Lin Xie; Bo Du; Bingxi Lei
Journal:  Ann Transl Med       Date:  2021-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.